SINTX Technologies Obtains FDA Approval for SINAPTIC® Foot and Ankle Implant System
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 20 2025
0mins
Source: Newsfilter
FDA Clearance: SINTX Technologies received FDA 510(k) clearance for its SINAPTIC® Foot & Ankle Osteotomy Wedge System, allowing the company to enter the U.S. reconstructive foot and ankle surgery market, with a commercial launch planned for Q1 2026.
Innovative Biomaterial: The SINAPTIC system utilizes SINTX's proprietary silicon nitride, which offers advantages such as superior osteointegration, bacteriostatic properties, and enhanced imaging visibility, positioning it as a competitive alternative to traditional metal implants in orthopedic procedures.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SINT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SINT
Wall Street analysts forecast SINT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SINT is 16.00 USD with a low forecast of 16.00 USD and a high forecast of 16.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 3.320
Low
16.00
Averages
16.00
High
16.00
Current: 3.320
Low
16.00
Averages
16.00
High
16.00
About SINT
SINTX Technologies, Inc. is an advanced ceramics company that develops and commercializes materials, components, and technologies for medical and agribiotech applications. It is engaged in the research, development, and manufacturing of silicon nitride. Its core business includes biomedical applications and antipathogenic applications. It has been focused on medical grade silicon nitride. Spinal implants made from its silicon nitride have been implanted in humans. This established use, along with its inherent resistance to bacterial adhesion and bone affinity suggests that it may also be suitable in other fusion device applications such as arthroplasty implants, foot wedges, and dental implants. Its composition of silicon nitride antipathogenic powder may enable manufacturing surfaces that inactivate pathogens, thereby limiting the spread of infection and disease. It manufactures advanced ceramic powders and components in its manufacturing facilities based in Salt Lake City, Utah.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
SINTX Technologies to Present at Sidoti Year End Virtual Investor Conference
- Investor Conference: SINTX Technologies will present at Sidoti's Year End Virtual Investor Conference on December 10-11, 2025, which is expected to attract significant investor attention and enhance the company's visibility in the capital markets.
- Presentation Timing: The management team is scheduled to speak on December 10, 2025, at 3:15 PM ET, aiming to showcase their advanced silicon nitride biomaterials technology, potentially piquing the interest of prospective investors.
- One-on-One Meeting Arrangements: Investors can schedule one-on-one meetings with SINTX's management via email, facilitating deeper engagement and understanding of the company's business and technology, which may influence investment decisions.
- Company Background: Headquartered in Salt Lake City, Utah, SINTX Technologies is an advanced ceramics company focused on developing and commercializing silicon nitride biomaterials for medical and other high-value applications, demonstrating its innovative capabilities in the high-tech sector.
Continue Reading
SINTX Technologies to Present at Sidoti's Year End Virtual Investor Conference
- Investor Conference Appearance: SINTX Technologies will present at Sidoti's Year End Virtual Investor Conference on December 10-11, 2025, which is expected to attract significant investor attention and enhance the company's visibility in the capital markets.
- Presentation Schedule: The management team is scheduled to speak on December 10, 2025, at 3:15 PM ET, aiming to showcase their advanced silicon nitride biomaterials and related technologies, thereby increasing market awareness of their products.
- One-on-One Meeting Opportunities: Investors can schedule one-on-one meetings with SINTX's management via email, which not only helps deepen investor understanding of the company but may also facilitate potential investment opportunities.
- Company Background: Headquartered in Salt Lake City, Utah, SINTX Technologies focuses on developing and commercializing silicon nitride biomaterials for high-value applications, demonstrating its technological strength and market potential in the medical field.
Continue Reading